Medtronic Receives FDA Clearance for Nellcor Pulse Oximetry System With Nell-EQ Intelligent Processor, a New Technology Designed To Improve Reliability Across Diverse Patients and Conditions
AI-summarised brief · reviewed before publication
Medtronic has received FDA clearance for its Nellcor pulse oximetry system with Nell-EQ intelligent processor, a new technology designed to improve reliability across diverse patients and conditions. The Nell-EQ system uses advanced signal processing methods to support consistent and reliable oxygen saturation and pulse rate monitoring. This regulatory milestone follows positive verification study results announced earlier this year and a previous FDA Safer Technologies Program designation. The technology is designed to support inclusive care and has been tested across a range of skin tones. It also supports additional parameters such as Perfusion Index and Heart Rate Variability.